Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
16 September 2022Website:
http://www.nexalin.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:59:40 GMTDividend
Analysts recommendations
Institutional Ownership
NXL Latest News
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses were approximately $5,250,000.
Nexalin Technology (NASDAQ: NXL ) stock is down on Friday after the medical device company priced a public offering of its shares. Nexalin Technology is selling 3 million shares of NXL stock for $1.75 each in this public offering.
HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $5,250,000.
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City.
Nexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury (mTBI). The company said that the study, conducted at the University of California San Diego, achieved a statistically significant decrease in post-concussion symptoms and post-traumatic stress disorder symptoms for patients treated with Nexalin's non-invasive, frequency-based deep brain stimulation device when compared to the control group.
What type of business is Nexalin Technology?
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
What sector is Nexalin Technology in?
Nexalin Technology is in the Healthcare sector
What industry is Nexalin Technology in?
Nexalin Technology is in the Medical Devices industry
What country is Nexalin Technology from?
Nexalin Technology is headquartered in United States
When did Nexalin Technology go public?
Nexalin Technology initial public offering (IPO) was on 16 September 2022
What is Nexalin Technology website?
https://www.nexalin.com
Is Nexalin Technology in the S&P 500?
No, Nexalin Technology is not included in the S&P 500 index
Is Nexalin Technology in the NASDAQ 100?
No, Nexalin Technology is not included in the NASDAQ 100 index
Is Nexalin Technology in the Dow Jones?
No, Nexalin Technology is not included in the Dow Jones index
When does Nexalin Technology report earnings?
Next earnings report date is not announced yet